Low-grade serous carcinomas of the ovary contain very few point mutations
- PMID: 22102435
- PMCID: PMC3503448
- DOI: 10.1002/path.3967
Low-grade serous carcinomas of the ovary contain very few point mutations
Abstract
It has been well established that ovarian low-grade and high-grade serous carcinomas are fundamentally different types of tumours. While the molecular genetic features of ovarian high-grade serous carcinomas are now well known, the pathogenesis of low-grade serous carcinomas, apart from the recognition of frequent somatic mutations involving KRAS and BRAF, is largely unknown. In order to comprehensively analyse somatic mutations in low-grade serous carcinomas, we applied exome sequencing to the DNA of eight samples of affinity-purified, low-grade, serous carcinomas. A remarkably small number of mutations were identified in seven of these tumours: a total of 70 somatic mutations in 64 genes. The eighth case displayed mixed serous and endometrioid features and a mutator phenotype with 783 somatic mutations, including a nonsense mutation in the mismatch repair gene, MSH2. We validated representative mutations in an additional nine low-grade serous carcinomas and 10 serous borderline tumours, the precursors of ovarian low-grade, serous carcinomas. Overall, the genes showing the most frequent mutations were BRAF and KRAS, occurring in 10 (38%) and 5 (19%) of 27 low-grade tumours, respectively. Except for a single case with a PIK3CA mutation, other mutations identified in the discovery set were not detected in the validation set of specimens. Our mutational analysis demonstrates that point mutations are much less common in low-grade serous tumours of the ovary than in other adult tumours, a finding with interesting scientific and clinical implications.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Conflict of interest statement
Conflicts of interest. Under agreements between the Johns Hopkins University, Genzyme, Exact Sciences, Inostics, Qiagen, Invitrogen and Personal Genome Diagnostics, KWK, VEV, BV and NP are entitled to a share of the royalties received by the University on sales of products related to genes and technologies described in this manuscript. KWK, VEV, BV and NP are co-founders of Inostics and Personal Genome Diagnostics, are members of their Scientific Advisory Boards and own Inostics and Personal Genome Diagnostics stock, which is subject to certain restrictions under Johns Hopkins University policy.
Figures

Similar articles
-
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252. J Pathol. 2013. PMID: 24549645 Free PMC article.
-
Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.Am J Surg Pathol. 2009 Aug;33(8):1220-4. doi: 10.1097/PAS.0b013e3181a24354. Am J Surg Pathol. 2009. PMID: 19461510 Free PMC article.
-
Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.J Pathol. 2014 Jan;232(1):16-22. doi: 10.1002/path.4293. J Pathol. 2014. PMID: 24307542 Free PMC article.
-
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.Adv Anat Pathol. 2009 Sep;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa. Adv Anat Pathol. 2009. PMID: 19700937 Free PMC article. Review.
-
Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23. Cancer Treat Rev. 2015. PMID: 25573350 Review.
Cited by
-
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.J Natl Cancer Inst. 2012 Oct 3;104(19):1503-13. doi: 10.1093/jnci/djs345. Epub 2012 Aug 23. J Natl Cancer Inst. 2012. PMID: 22923510 Free PMC article.
-
Diagnostic potential of tumor DNA from ovarian cyst fluid.Elife. 2016 Jul 15;5:e15175. doi: 10.7554/eLife.15175. Elife. 2016. PMID: 27421040 Free PMC article.
-
Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.Nat Commun. 2014 Sep 19;5:5006. doi: 10.1038/ncomms6006. Nat Commun. 2014. PMID: 25233892 Free PMC article.
-
Targeted Therapies in Low-Grade Serous Ovarian Cancers.Curr Treat Options Oncol. 2024 Jul;25(7):854-868. doi: 10.1007/s11864-024-01205-4. Epub 2024 Jun 13. Curr Treat Options Oncol. 2024. PMID: 38869696 Free PMC article. Review.
-
Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells.Am J Pathol. 2012 Mar;180(3):1179-1188. doi: 10.1016/j.ajpath.2011.11.026. Epub 2012 Jan 5. Am J Pathol. 2012. PMID: 22227015 Free PMC article.
References
-
- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
-
- Plaxe SC. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol. 2008;198:459, e1–e8. discussion, e8-9. - PubMed
-
- Grimley PM, Matsuno RK, Rosenberg PS, et al. Qualitative age interactions between low-grade and high-grade serous ovarian carcinomas. Cancer Epidemiol Biomarkers Prev. 2009;18:2256–2261. - PubMed
-
- Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II–IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108:361–368. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA116184/CA/NCI NIH HHS/United States
- CA121113/CA/NCI NIH HHS/United States
- R01 CA121113/CA/NCI NIH HHS/United States
- CA129080/CA/NCI NIH HHS/United States
- U24 CA160036/CA/NCI NIH HHS/United States
- R01 CA103937/CA/NCI NIH HHS/United States
- CA103937/CA/NCI NIH HHS/United States
- R37 CA043460/CA/NCI NIH HHS/United States
- CA160036/CA/NCI NIH HHS/United States
- CA43460/CA/NCI NIH HHS/United States
- CA1165807/CA/NCI NIH HHS/United States
- R01 CA116184/CA/NCI NIH HHS/United States
- R01 CA129080/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous